Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

Avalo will share Phase 2 LOTUS trial data for abdakibart in hidradenitis suppurativa through late‑breaker oral and poster sessions at EADV 2026.

Rhea-AI Summary

Avalo Therapeutics (AVTX) will present new clinical data on its IL‑1β‑targeting therapies for hidradenitis suppurativa at the EADV Congress 2026 in Vienna, Austria from September 30–October 3, 2026.

The company will deliver a late‑breaker oral presentation on October 1, 2026 at 5:00pm CEST in Hall A, covering week‑16 efficacy and safety results of abdakibart (ABD) from the placebo‑controlled Phase 2 LOTUS trial, including IHS4 subgroup and lesion type ANdT analyses. A poster presentation on September 30, 2026 at 7:00am CEST in the ePoster Area (Inflammatory Skin Diseases – Part II) will report primary results of the same Phase 2 LOTUS trial. Avalo is advancing abdakibart into a Phase 3 registrational program in hidradenitis suppurativa and is also developing AVTX‑010, a long‑acting next‑generation anti‑IL‑1β monoclonal antibody.

Key Terms

igg4, hidradenitis suppurativa, monoclonal antibody (mAb)

3 terms

igg4 medical

"a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent"

IgG4 is a specific subtype of antibody the immune system makes; antibodies are proteins that identify and bind to foreign substances. Think of IgG4 as a specialized model of a tool that behaves differently from other antibodies—sometimes calming inflammation and sometimes signaling particular allergic or autoimmune conditions. For investors, IgG4 matters because its levels can drive demand for diagnostics, influence the course or approval of drugs and biologics, and serve as a clinical or safety signal that affects biotech and healthcare valuations.

hidradenitis suppurativa medical

"Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

monoclonal antibody (mAb) medical

"lead anti-IL-1β monoclonal antibody (mAb) drug candidate"

A monoclonal antibody (mAb) is a lab-made protein engineered to recognize and stick to one specific molecule in the body, like a guided missile or a key fitting a single lock. For investors, mAbs matter because their clinical trial results, regulatory approvals, patent position and manufacturing complexity can drive a company’s future sales, costs and risk profile, making them major value drivers in healthcare stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.

EADV Congress 2026 Presentation Details:

Late-Breaker Oral Presentation:

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of the Phase 2 Placebo Controlled LOTUS Trial
Presenter: Dr. Martina Porter, Assistant Professor of Dermatology at Harvard Medical School and Vice Chair for Research and Academics, Department of Dermatology at Beth Israel Deaconess Medical Center
Location: Hall A
Date: Thursday, October 1, 2026 5:00pm CEST

Poster Presentation:

Title: Efficacy and Safety of Abdakibart, a Selective Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa; Primary Results of the Placebo-Controlled Phase 2 LOTUS Trial
Location: ePoster Area; Inflammatory Skin Diseases – Part II
Date: Wednesday, September 30, 2026 7:00am CEST

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com